Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica

Abstract

Objective

To evaluate clinical characteristics, aquaporin (AQP)-4 antibody results, and probability of developing symptoms of neuromyelitis optica (NMO) in patients with Sjögren’s syndrome myelopathy (SSM).

Methods

We identified eight patients with spinal cord involvement from 112 patients with Sjögren’s syndrome (SS) referred to the neurology department. The clinical characteristics and AQP-4 antibody status, based on immunoprecipitation of EGFP-tagged AQP-4, of the patients with SSM were assessed.

Results

All patients with SSM had extensive spinal cord lesions, high mean annual relapse rates, and poor response to steroid treatment. Of the eight patients with SSM, seven patients satisfied the revised diagnostic criteria for NMO or showed positive results from AQP-4 antibody testing; one patient had incomplete follow-up. The clinical manifestations and AQP-4 autoantibody status of patients with SSM did not differ significantly from those of NMO patients without SS.

Conclusion

All patients with SSM had poor prognosis with high mean annual relapse rates, and most seemed to have the clinical and immunological characteristics of NMO. Early aggressive immune therapies should be considered in patients with SSM irrespective of the presence or absence of optic neuritis.

Keywords

AQP-4 myelopathy neuromyelitis optica relapse/remitting Sjögren spinal cord

Get full access to this article

View all access options for this article.

References

1 Vitali C Bombardieri S Jonsson R . Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.

2 Delalande S de Seze J Fauchais AL . Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83: 280–291.

3 Pericot I Brieva L Tintore M Rio J Sastre-Garriga J Montalban C . Myelopathy in seronegative Sjogren syndrome and/or primary progressive multiple sclerosis. Mult Scler 2003; 9: 256–259.

4 Waters P Jarius S Littleton E . Aquaporin-4 antibodies in neuromyelitis optica and longitudinally-extensive transverse myelitis. Arch Neurol 2008; 65: 913–919.

5 Wingerchuk DM Lennon VA Pittock SJ Lucchinetti CF Weinshenker BG . Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.

6 Pittock SJ Lennon VA de Seze J . Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65: 78–83.

7 Hayakawa S Mori M Okuta A . Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008; 196: 181–187.

8 Arabshahi B Pollock AN Sherry DD Albert DA Kreiger PA Pessler F . Devic disease in a child with primary Sjögren syndrome. J Child Neurol 2006; 21: 285–286.

9 Pantoni L Garcia JH . The significance of cerebral white matter abnormalities 100 years after Binswanger's report: a review. Stroke 1995; 26: 1293–1301.

10.

10 Pittock S Weinshenker B Lucchinetti C Wingerchuk D Corboy J Lennon V . Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63: 964–968.

11.

11 Pittock S Lennon V Krecke K Wingerchuk D Lucchinetti C Weinshenker B . Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390–396.

12.

12 Jacob A Matiello M Wingerchuk D Lucchinetti C Pittock S Weinshenker B . Neuromyelitis optica: changing concepts. J Neuroimmunol 2007; 187: 126–138.

13.

13 Williams CS Butler E Román GC . Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001; 58: 815–819.

14.

14 Yamout B El-Hajj T Barada W Uthman I . Successful treatment of refractory neuroSjogren with Rituximab. Lupus 2007; 16: 521–523.

15.

15 Wingerchuk DM Hogancamp WF O’Brien PC Weinshenker BG . The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53: 1107–1114.

16.

16 Steinfeld S Cogan E King LS Agre P Kiss R Delporte C . Abnormal distribution of aquaporin-5 water channel protein in salivary gland from Sjogren’s syndrome. Lancet 2001; 357: 688–689.